Precis: In our experience, indeterminate diagnoses (FLUS+FN+SM) accounted for the majority (60%) of preoperative FNAs for incidental microcarcinoma (size ≤0.5 cm) when compared to 27% for those of non-incidental microcarcinoma (size >0.5 cm and ≤1 cm) (p<0.05, chi-square test).
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MANUSCRIPT TEXT: INTRODUCTION:
Thyroid cancer is the most common malignancy of the endocrine system, and the incidence has dramatically increased in recent years. The majority of cases consist of papillary thyroid carcinoma (PTC), making up more than 80% of histologic diagnoses. [1] [2] [3] A paramount study with the Surveillance, Epidemiology, and End Results (SEER) data exhibited a nearly threefold increase in PTC from 1973 to 2009. 1, 4 The bulk of this increase was shown to be associated with an upsurge in cancers of smaller size. Microcarcinoma, defined as measuring ≤1 cm by the World Health Organization, comprised 49% of the increase in incidence. 1, 5 It is unclear whether the rising incidence is a true epidemic of disease or reflects the enhanced detection of thyroid nodules with advanced imaging techniques. 1, 6 Many nodules are discovered during the use of head and neck imaging for unrelated symptoms. Widespread use of ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography allows for detection of smaller thyroid nodules. Ultrasound imaging can detect nodules as small as 0.2 cm in dimension, but the clinical significance of these findings is highly debated. 1, 7 Microcarcinoma is generally thought to have an indolent nature, presenting as an ancillary finding at the time of histologic examination. Foci of papillary thyroid microcarcinoma have been reported in up to 22% of surgical thyroid specimens and up to 36% of autopsy series. 6, [8] [9] [10] [11] However, its biologic behavior can be variable with associated morbidity and mortality. Some patients have local lymph node metastases or distant metastases at the time of diagnosis or during years of follow-up. 7, [12] [13] Other authors have even reported cancer-related deaths.
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A pioneer study in 1987 described a higher rate of lymph node metastasis in patients with thyroid microcarcinoma >0.5 cm when compared to microcarcinoma ≤0.5 cm. 15 Since that publication, many research groups have examined the significance of various clinicopathologic risk factors with an established size cutoff of 0.5 cm. [16] [17] [18] [19] One study corroborated the finding of an increased incidence of lymph node metastasis in patients with microcarcinoma >0.5 cm, supporting the importance of this size distinction. 16 A second publication went further to report the cutoff of >0.5 cm to be an independent predictor of subclinical central lymph node metastasis. 19 Another study found a significant difference in extrathyroidal extension in patients with microcarcinoma >0.5 cm. 17 There is potential value in using 0.5 cm as a size parameter when analyzing microcarcinoma.
Standard of care for thyroid cancer and lymph node involvement is total thyroidectomy with central lymph node dissection. 19 However, the rise in both incidental and non-incidental microcarcinoma has generated controversy surrounding optimal management. There is little epidemiologic data on the broad spectrum of disease characteristics and long-term prognosis of microcarcinoma. 20 Recommendations for clinical management range from observation alone to total thyroidectomy with lymph node dissection and radioactive iodine. 2, 8, 12, [20] [21] [22] Ultrasound-guided fine-needle aspiration (FNA) is a fundamental component to the preoperative evaluation of thyroid nodules. It is a safe and minimally invasive modality, separating nodules into well-defined diagnostic tiers to steer appropriate patient care. 9 Nevertheless, there is little known about the relationship between microcarcinoma and cytologic categories on FNA.
Microcarcinoma has a clear impact on the increasing incidence of thyroid cancer. We sought to investigate the correlation between microcarcinoma and preoperative cytology to facilitate communication with clinicians.
MATERIALS AND METHODS:
This study was approved by the Institutional Review Board of Indiana University. A retrospective analysis of thyroid FNAs performed at our institution was conducted for the 5-year period from 2010 to 2014. All aspirates were categorized into six groups using the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC).
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A computer search of the anatomic pathology archives and the electronic medical record was performed to document the histologic results of patients who underwent surgery. The cytologic diagnoses were then correlated with the final histopathology. In cases with multiple nodules, preoperative FNAs were matched with corresponding histology based on the location in the thyroid gland when that information was available. Identification of biopsy related changes in direct association with nodules was beyond the scope of this retrospective study.
Among the samples with malignancy on surgical resection, nodules were stratified by size.
According to the criteria outlined by the World Health Organization, thyroid microcarcinoma was designated as 1 cm or less in greatest dimension. 5 To further classify microcarcinoma, there are different definitions for incidental and non-incidental microcarcinoma in the literature. For our statistical analysis, we used size as the deciding factor. Previous studies highlight tumor size as an important clinicopathologic factor, but various size cutoffs have been applied. There are
reports of higher rates of lymph node metastases and extrathyroidal extension in cases >0.5
cm. [15] [16] [17] [18] [19] It provides support to our designation of 0.5 cm as a reasonable size cutoff. In our study, malignant nodules ≤0.5 cm were classified as incidental microcarcinoma. In contrast, nodules >0.5 cm and ≤1 cm were delineated as non-incidental microcarcinoma.
In order to address the recent revision in nomenclature, the cases previously diagnosed as encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) were reassessed. Two cases originated at an outside institution, and these slides were not available for review. The reported diagnoses were maintained for our analysis. All other slides were examined by a boardcertified pathologist (HHW). The prevailing diagnostic criteria for noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) were applied as necessary.
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A chi-square test using an online calculator was performed to compare the rate of indeterminate FNA diagnoses between the group of incidental microcarcinoma and non-incidental microcarcinoma. The result was found to be significant at p<0.05
(http://www.socscistatistics.com/tests/chisquare/Default.aspx).
RESULTS:
A total of 2531 thyroid FNA samples were identified, and 587 FNAs had surgical follow-up with histologic correlation. 259 malignant thyroid nodules were found in 220 patients (167 females, 53 males) with an age range of 16 to 88 years. They were associated with preoperative cytologic diagnoses as follows: benign (B, n=27, 10%), follicular lesion of undetermined significance
(FLUS, n=40, 15%), follicular neoplasm (FN, n=23, 9%), suspicious for malignancy (SM, n=36, 14%), malignant (M, n=126, 49%), and non-diagnostic (ND, n=7, 3%) ( Table 1) .
Malignancies were separated by size into nodules >1 cm (n=144, 56%) and microcarcinomas ≤1 cm (n=115, 44%). With the nodules >1 cm, final histopathology showed evidence of sizes ranging from 1.1 to 13 cm in greatest dimension (Table 1 ). Among cases of thyroid microcarcinoma, the nodules were 0.1 to 1.0 cm in size.
With the initial separation by size, malignant nodules >1 cm correlated with the following preoperative cytologic diagnoses: B (n=3, 2%), FLUS (n=22, 15%), FN (n=9, 6%), SM (n=19, 13%), M (n=89, 62%), and ND (n=2, 1%) ( Table 1) .
Microcarcinoma was further subdivided into incidental microcarcinoma (size ≤0.5 cm, n=55, 48%) and non-incidental microcarcinoma (size >0.5 cm and ≤1 cm, n=60, 52%) ( Table 1 ). The corresponding preoperative cytologic diagnoses for incidental microcarcinoma were: B (n=11, 20%), FLUS (n=15, 27%), FN (n=11, 20%), SM (n=7, 13%), M (n=8, 15%), and ND (n=3, 5%) ( Table 1 ). The cytologic diagnoses for non-incidental microcarcinoma were: B (n=13, 22%), FLUS (n=3, 5%), FN (n=3, 5%), SM (n=10, 17%), M (n=29, 48%) and ND (n=2, 3%) ( Table 1 ).
According to the new paradigm shift, reclassification of cases revealed 10 nodules >1 cm , and metastatic renal cell carcinoma (4/134, 3%). These nodules correlated with the following cytologic diagnoses: B (n=1, 1%), FLUS (n=17, 13%), FN (n=8, 6%), SM (n=18, 13%), M (n=89, 66%), and ND (n=1, 1%) ( Table 2) .
With the non-incidental micronodules (>0.5 cm and ≤1 cm), 4 cases could be categorized as NIFTP (4/60, 7%) ( Incidental microcarcinoma ≤0.5 cm consisted of PTC (n=32, 58%), FVPTC (n=20, 36%), and MTC (n=3, 6%) ( Table 4 ). In the category of FVPTC, a total of 10 cases were partially encapsulated (10/20, 50%), and 7 had no capsule (7/20, 35%). None of these 17 cases showed evidence of lymphovascular invasion or extrathyroidal extension; however, they are too small to be classified as NIFTP. One case displayed minimal capsular invasion. Furthermore, one case demonstrated a concurrent lymph node metastasis, and one case had lymphovascular invasion.
Of note, the case with lymph node metastasis had a clinical history of classic papillary thyroid carcinoma on the contralateral side, status post hemithyroidectomy. Also, the case with lymphovascular invasion had a synchronous papillary thyroid carcinoma on the opposite side.
The presence of a metastasis cannot be completely excluded in these two scenarios. Lastly, one case originated at an outside institution, and the slides were not available for review. The
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DISCUSSION:
Among prognostic factors related to thyroid carcinoma, the most controversial aspect is the tumor size. Most cases of microcarcinoma have an indolent clinical course, and some clinicians believe nodules ≤1 cm should not be biopsied. 7 However, there is a subset of patients with aggressive disease who present with bulky lymph node involvement and/or distant metastases. 7, [12] [13] [14] Fine-needle aspiration is indispensable to the evaluation of thyroid nodules, and it facilitates risk stratification of patients. Little data has been published on the relationship between microcarcinoma and the preoperative classification according to TBSRTC. We sought to evaluate the cytologic diagnoses of thyroid FNAs and correlate it with the final histopathology of microcarcinoma.
While the majority of malignant nodules had a size >1 cm (144/259, 56%), the presence of microcarcinoma was also evident in our population (115/259, 44%) ( Table 1) . Incidental thyroid microcarcinoma with size ≤0.5 cm is not an uncommon entity. It accounted for 21% (55/259) of malignant nodules that were discovered on follow-up thyroidectomy. It was similar in value to non-incidental microcarcinoma (size >0.5 cm and ≤1 cm) (23%, 60/259) ( Table 1) .
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Not surprisingly, most malignant nodules >1 cm were associated with the cytologic category of malignant (89/144, 62%) (Table 1) . Nevertheless, this did not hold true with microcarcinoma in our population. Indeterminate categories (FLUS+FN+SM) accounted for the majority (60%) of preoperative FNA diagnoses for incidental microcarcinoma when compared to 27% for those of non-incidental microcarcinoma (p<0.05, chi-square test) ( Table 1 ).
This data was compiled and analyzed before the recent publication supporting a paradigm shift to revise the nomenclature used in thyroid pathology. After gathering our original data, a second tier of analysis was performed to address the new terminology of NIFTP. 24 The inclusion criteria were created based on evaluation of tumors ≥1 cm, yet there was no minimum size established for future application of the diagnosis. 25 To thoroughly explore the issue, we examined tumors of all sizes with the diagnosis of EFVPTC in the final pathology report.
The task of reclassifying the malignancies generated only a slight adjustment in the statistical results. Of the original 204 malignant nodules that were >0.5 cm, review of the cases of EFVPTC revealed only 14 cases (7%) met the criteria to now be defined as NIFTP. 24 In our population, most of these cases were >1 cm in size (10/14). The remaining cases were nonincidental micronodules with size >0.5 cm and ≤1 cm (4/14) ( Table 3) . None of the incidental microcarcinomas necessitated a new classification (Table 4) .
Several recent studies on the characteristics of thyroid microcarcinoma and aspects associated with aggressive disease found size to be an important risk factor. In one retrospective cohort, microcarcinoma ≥0.8 cm was shown to be associated with neck lymph node involvement and M A N U S C R I P T
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distant metastases at presentation and recurrence of disease at follow-up. 11 Another study uncovered increased risk for central lymph node metastases in tumors ≥0.6 cm. 26 Lastly, longterm follow-up in Japan found patients with tumor size of 0.1-0.5 cm had an improved recurrence-free survival rate 35 years after surgery when compared to patients with tumor size of 0.6-1.0 cm. 20 The exact size predictive of aggressive disease in microcarcinoma appears to slightly vary with the study population. Our distinction of non-incidental microcarcinoma (>0.5 cm and ≤1 cm) and incidental microcarcinoma (≤0.5 cm) is in accordance with the separation points used in other analyses. [15] [16] [17] [18] [19] [20] 26 After exclusion of NIFTP, the indeterminate categories (FLUS+FN+SM) still accounted for the majority (60%) of preoperative FNA diagnoses for incidental microcarcinoma when compared to 25% for those of non-incidental microcarcinoma (p<0.05, chi-square test) ( Table 2) .
These results can presumably be attributed to a sampling issue inherent to the procedure and not solely an interpretation error. The cytologic diagnoses were rendered by multiple different boardcertified pathologists and often with use of intradepartmental consensus. With our designation of ≤0.5 cm as incidental microcarcinoma, it is reasonable to surmise that many of these were indeed Earlier studies indicated that microcarcinoma was an entity mostly discovered in thyroid glands removed for benign disease or at the time of autopsy. Recent trends in cancer surveillance and advanced diagnostic techniques have contributed to a shift in size distribution toward smaller tumors. 1, 4, 27 Due to the uncertain behavior of microcarcinoma, the use of FNA on thyroid nodules ≤1 cm has been a frequent topic of debate. 10 The 2015 American Thyroid Association guidelines discourage using FNA to evaluate subcentimeter thyroid nodules in patients without evidence of extrathyroidal extension or a sonographically suspicious lymph node. 28 However, current recommendations justify the use of FNA to assess nodules ≤1 cm with worrisome features such as hypoechogenicity, irregular margins, and microcalcifications on ultrasound imaging.
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Regardless of size, thyroid nodules with suspicious findings can be subjected to preoperative evaluation with fine-needle aspiration. Our analysis highlights the incidence of microcarcinoma and its correlation with each FNA category. Although the cytology smears may not be definitive, this should not deter clinicians from using fine-needle aspiration to assess smaller nodules. 
